Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing
pain related to diabetic peripheral neuropathy over an 11 week assessment period.